127 related articles for article (PubMed ID: 2860603)
21. Processing of prodynorphin-derived peptides in striatal extracts. Identification by electrospray ionization mass spectrometry linked to size-exclusion chromatography.
Nylander I; Tan-No K; Winter A; Silberring J
Life Sci; 1995; 57(2):123-9. PubMed ID: 7603294
[TBL] [Abstract][Full Text] [Related]
22. Steady-state levels of pro-dynorphin-related end-products from the brain of the amphibian, Xenopus laevis.
Sei CA; Richard R; Dores RM
Brain Res; 1989 Feb; 479(1):162-6. PubMed ID: 2564304
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical evidence for different opioid systems in the rat superior cervical ganglion as revealed by imipramine treatment and receptor blockade.
Folan JC; Heym C
J Chem Neuroanat; 1989; 2(2):107-18. PubMed ID: 2574980
[TBL] [Abstract][Full Text] [Related]
24. Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.
Engber TM; Susel Z; Kuo S; Gerfen CR; Chase TN
Brain Res; 1991 Jun; 552(1):113-8. PubMed ID: 1717109
[TBL] [Abstract][Full Text] [Related]
25. Analysis of opioid and non-opioid end products of pro-dynorphin in the substantia nigra of the rat.
Dores RM; Lewis ME; Khachaturian H; Watson SJ; Akil H
Neuropeptides; 1985 Feb; 5(4-6):501-4. PubMed ID: 2860608
[TBL] [Abstract][Full Text] [Related]
26. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
[TBL] [Abstract][Full Text] [Related]
27. Evolution of gnathostome prodynorphin and proenkephalin: characterization of a shark proenkephalin and prodynorphin cDNAs.
Komorowski LK; Lecaude SG; Westring CG; Danielson PB; Dores RM
Gen Comp Endocrinol; 2012 Jul; 177(3):353-64. PubMed ID: 22210245
[TBL] [Abstract][Full Text] [Related]
28. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats.
Nylander I; Vlaskovska M; Terenius L
Psychopharmacology (Berl); 1995 Apr; 118(4):391-400. PubMed ID: 7568625
[TBL] [Abstract][Full Text] [Related]
29. Variations in opioid peptide levels during the estrous cycle in Sprague-Dawley rats.
Roman E; Ploj K; Gustafsson L; Meyerson BJ; Nylander I
Neuropeptides; 2006 Jun; 40(3):195-206. PubMed ID: 16540166
[TBL] [Abstract][Full Text] [Related]
30. The distribution of dynorphinergic terminals in striatal target regions in comparison to the distribution of substance P-containing and enkephalinergic terminals in monkeys and humans.
Reiner A; Medina L; Haber SN
Neuroscience; 1999; 88(3):775-93. PubMed ID: 10363817
[TBL] [Abstract][Full Text] [Related]
31. Species-specific processing of prodynorphin in the posterior pituitary of mammals.
Dores RM; Akil H
Endocrinology; 1987 Jan; 120(1):230-8. PubMed ID: 3780560
[TBL] [Abstract][Full Text] [Related]
32. Distribution pattern of metorphamide compared with other opioid peptides from proenkephalin and prodynorphin in the bovine brain.
Sonders M; Weber E
J Neurochem; 1987 Sep; 49(3):671-80. PubMed ID: 3612117
[TBL] [Abstract][Full Text] [Related]
33. Hemodynamic responses of conscious rats following intrathecal injections of prodynorphin-derived opioids: independence of action of intrathecal arginine vasopressin.
Thornhill JA; Pittman QJ
Can J Physiol Pharmacol; 1990 Feb; 68(2):174-82. PubMed ID: 1968777
[TBL] [Abstract][Full Text] [Related]
34. Chronic haloperidol and clozapine differentially affect dynorphin peptides and substance P in basal ganglia of the rat.
Nylander I; Terenius L
Brain Res; 1986 Aug; 380(1):34-41. PubMed ID: 2428423
[TBL] [Abstract][Full Text] [Related]
35. Methionine and leucine enkephalin in rat neurohypophysis: different responses to osmotic stimuli and T2 toxin.
Zamir N; Zamir D; Eiden LE; Palkovits M; Brownstein MJ; Eskay RL; Weber E; Faden AI; Feuerstein G
Science; 1985 May; 228(4699):606-8. PubMed ID: 2858918
[TBL] [Abstract][Full Text] [Related]
36. Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease.
Ljungdahl A; Hanrieder J; Fälth M; Bergquist J; Andersson M
PLoS One; 2011; 6(9):e25653. PubMed ID: 21984936
[TBL] [Abstract][Full Text] [Related]
37. Habenular modulation of dynorphinergic systems in rat ventral mesencephalon.
Ichikawa H; Nishikawa T; Mitsushio H; Takashima M
Peptides; 1988; 9(5):1107-14. PubMed ID: 2469061
[TBL] [Abstract][Full Text] [Related]
38. Effects of dynorphin (1-8) on movement: non-opiate effects and structure-activity relationship.
Friederich MW; Friederich DP; Walker JM
Peptides; 1987; 8(5):837-40. PubMed ID: 2893358
[TBL] [Abstract][Full Text] [Related]
39. Corticotropin-releasing factor stimulates the release of methionine-enkephalin and dynorphin from the neostriatum and globus pallidus of the rat: in vitro and in vivo studies.
Sirinathsinghji DJ; Nikolarakis KE; Herz A
Brain Res; 1989 Jun; 490(2):276-91. PubMed ID: 2569903
[TBL] [Abstract][Full Text] [Related]
40. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
Jiang HK; McGinty JF; Hong JS
Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
